| Ticker Details |
Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.
|
| IPO Date: |
June 26, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$559.85M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.72 | 3.26%
|
| Avg Daily Range (30 D): |
$0.10 | 3.82%
|
| Avg Daily Range (90 D): |
$0.10 | 3.20%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.75M |
| Avg Daily Volume (30 D): |
5.51M |
| Avg Daily Volume (90 D): |
4.71M |
| Trade Size |
| Avg Trade Size (Sh.): |
221 |
| Avg Trade Size (Sh.) (30 D): |
319 |
| Avg Trade Size (Sh.) (90 D): |
291 |
| Institutional Trades |
| Total Institutional Trades: |
3,200 |
| Avg Institutional Trade: |
$1.77M |
| Avg Institutional Trade (30 D): |
$.97M |
| Avg Institutional Trade (90 D): |
$1.24M |
| Avg Institutional Trade Volume: |
.12M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$1.02M |
| Avg Closing Trade (90 D): |
$1.24M |
| Avg Closing Volume: |
130.15K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-.11
|
$.32
|
$-.11
|
|
Diluted EPS
|
$-.11
|
$.32
|
$-.11
|
|
Revenue
|
$403.14M
|
$168.45M
|
$403.14M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-22.68M
|
$61.83M
|
$-22.68M
|
|
Operating Income / Loss
|
$60.27M
|
$85.23M
|
$60.27M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$M
|
$M
|
$M
|
|
PE Ratio
|
|
|
|
|
|
|
